COMBINAISONS D'ANTICORPS CIBLANT LES RÉCEPTEURS DU FACTEUR DE CROISSANCE ÉPIDERMIQUE POUR TRAITER LE CANCER

• 收藏
• 分享

专利权人:

Ltd.;Yeda Research and Development Co.

发明人:

申请号：

EP18202727.6

公开号：

EP3584259A1

申请日:

2013.10.17

申请国别(地区):

EP

年份:

2019

代理人:

摘要：

The present invention relates to the use of an anti-EGFR antibody combination for treating pancreatic cancer, wherein the combination comprises: (i) a first anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 (CNCM Deposit Number I-4262), wherein said first anti-EGFR antibody binds the same EGFR epitope as said anti EGFR 565； and (ii) a second anti-EGFR antibody comprising the CDR sequences of C225/Cetuximab, wherein said second anti-EGFR antibody binds the same EGFR epitope as said C225/Cetuximab.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/